Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

On November 11, 2026 Tempus AI, Inc. (NASDAQ: TEM) reported that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This research leverages Tempus’ expansive, de-identified multimodal library, which includes a cohort of 45,085 real-world patients across 615 rare and ultra-rare cancer types. Within this comprehensive repository, sarcomas are among the most well-represented cancer types. This deep data foundation directly enabled the clinical findings being presented at CTOS, demonstrating the power of comprehensive multimodal profiling—including DNA matched tumor/normal sequencing, whole transcriptomic analysis, and digital pathology informatics—to reveal actionable insights.

"In rare diseases, such as sarcoma, small patient datasets make uncovering insights exceptionally challenging, which is where Tempus’ robust dataset brings critical value," said Ezra Cohen M.D., Chief Medical Officer of Oncology at Tempus. "Importantly, Tempus is dedicated through its Orphan Disease Program to providing solutions to the inherent barriers in rare cancers, and to helping physicians develop and tailor therapies more precisely."

Oral Presentations

Thursday, November 19, 2026 | 2:15 PM – 3:15 PM KST

Melanoma-Associated Antigen A4 (MAGE-A4) mRNA Expression and Tumor Immune Micro-Environment (TIME) as Biomarkers in Sarcoma: A Real-World Clinicogenomic Study
Friday, November 20, 2026 | 4:15 PM – 5:15 PM KST

Distinct DNA Damage Response (DDR) Transcriptional Signature is Enriched in a Subset of SDH-Deficient GIST: Implications for Temozolomide Sensitivity
Transcriptomic Subtyping of 1,490 GIST Patients Identifies Prognostic Risk Groups Superior to Clinical and Molecular Variables
Poster Presentations

Transcriptional Programs Associated with Response to Pazopanib in Metastatic Bone and Soft Tissue Sarcoma
Molecular and Genomic Characteristics of Desmoplastic Small Round Cell Tumor
Improving Germline Variant Detection in Sarcoma via Matched Tumor/Normal Sequencing: A Real-World Analysis of 9,025 Patients

(Press release, Tempus, NOV 11, 2026, View Source [SID1234674622])

Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026

On November 11, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET / 4:00 PM GMT, in London, at the IET London, Savoy Place.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium.

The event will include a review of the Phase 1 study’s safety, pharmacokinetic and antitumor activity findings, along with a discussion of the current treatment landscape and unmet medical need in urothelial cancer. Professor Loriot will provide his clinical perspective, while Innate management will discuss the scientific rationale for IPH4502 and next steps in its clinical development.

A live question-and-answer session will follow the formal presentations.

Event details

Event: IPH4502 Phase 1 clinical data and development outlook
Date and time: November 18, 2026 at 11:00 a.m. ET / 4:00 p.m. GMT
Location: IET London, Savoy Place, 2 Savoy Place, London WC2R 0BL, United Kingdom
To register for in person participation or virtual access, click here.
A replay will be available in the investors section of Innate Pharma website after the event.

About Professor Yohann Loriot, M.D., Ph.D.

Professor Yohann Loriot is a medical oncologist and Professor of Medicine at Gustave Roussy, specializing in genitourinary cancers, with a particular focus on bladder cancer. He serves as Deputy Head of the Department of Therapeutic Innovation and Early Drug Development (DITEP) and coordinates the UNLOCK program, dedicated to understanding mechanisms of sensitivity and resistance to innovative cancer therapies.

He holds both a Medical Degree and a PhD in Anticancer Pharmacology and teaches at Paris-Saclay University. His research focuses on the development of novel therapeutic strategies and the identification of mechanisms of treatment resistance in solid tumors, particularly urothelial and prostate cancers.

Professor Loriot has authored more than 300 peer-reviewed scientific publications and is an active member of several leading international scientific societies, including ESMO (Free ESMO Whitepaper), ASCO (Free ASCO Whitepaper) and AACR (Free AACR Whitepaper). He also leads the EORTC Urological Tumours Group and contributes to the development of European clinical guidelines in bladder cancer.

Scientific expert disclosure

Professor Yohann Loriot will participate as guest speaker and Gustave Roussy will receive compensation for his participation in the event, which doesn’t constitute an endorsement of the investigational product or a recommendation for its use.

About IPH4502

IPH4502 is Innate Pharma’s proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance, and without the need for CYP2D6 genotyping. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). In preclinical studies, IPH4502 demonstrated anti-tumor activity in EV-resistant tumor models and in tumors with low and heterogeneous Nectin-4 expression, supporting its potential applicability across solid tumor types beyond urothelial carcinoma (UC). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4.

IPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.

(Press release, Innate Pharma, NOV 11, 2026, View Source [SID1234674623])

Faeth Therapeutics to Participate in Upcoming November Investor Conferences

On November 11, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported that management will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim 3rd Annual Healthcare Innovation Conference
Wednesday, November 11, 2026
1×1 investor meetings
Boston, MA
Jefferies Global Healthcare Conference in London
Tuesday, November 17, 2026
Presentation at 8:30 AM GMT
London, UK
Webcast Link

Live webcasts of the presentation and fireside chats can be accessed via the Events and Presentations section of the Faeth website at investors.faeththerapeutics.com. Replays will be available for approximately 90 days following the event.

(Press release, Faeth Therapeutics, NOV 11, 2026, View Source [SID1234674608])

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma

On November 11, 2026 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, reported that it has entered into a clinical supply agreement with Coherus Oncology, Inc. ("Coherus") to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus’ next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), in a clinical study in patients with squamous cell anal carcinoma ("SCAC").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is expected to be conducted at a premier cancer center in the United States, which will be named once the study commences, and is anticipated to begin in the first quarter of 2027. It is expected to enroll patients who have progressed on the current standard-of-care first-line treatment of chemotherapy and checkpoint inhibition. Importantly, there is no approved therapy for second-line patients in this indication.

Under the terms of the clinical supply agreement, Coherus will provide LOQTORZI to Oncolytics, which is expected to partner with the institution sponsoring the planned clinical study.

"This agreement supports a focused clinical evaluation of pelareorep with a marketed PD-1 inhibitor in a difficult-to-treat patient population," said Jared Kelly, Chief Executive Officer of Oncolytics. "The planned study is designed to build upon the previous efficacy signals pelareorep has shown in second-line or later SCAC patients while getting data in a patient population that has progressed on the new first-line standard of care. If the results are supportive, we believe SCAC could provide an important first step toward evaluating this combination more broadly across HPV-associated cancers."

Rationale for the Pelareorep and Toripalimab Combination

Pelareorep is designed to activate toll-like receptor 3, stimulating innate and adaptive antitumor immune responses, and to promote the formation of tertiary lymphoid structures within the tumor, which have been associated with improved responses to checkpoint inhibitor therapy. Through these mechanisms, pelareorep promotes tumor-directed T-cell activation and infiltration and induces inflammatory signaling within the tumor microenvironment. Recent translational data presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting showed that pelareorep combined with a checkpoint inhibitor increases human papillomavirus ("HPV")-16-specific T cell clones and tumor-infiltrating lymphocyte clones in SCAC patients. Toripalimab blocks the PD-1 pathway, a mechanism tumors can use to suppress activated T cells. The planned study will evaluate whether pelareorep-mediated immune activation can enhance the antitumor activity of PD-1 blockade in SCAC patients who have progressed on chemo-immunotherapy treatment.

SCAC is an HPV-associated cancer with limited treatment options for patients whose disease progresses after available therapy. Because HPV-associated tumors express viral antigens that may provide recognizable immune targets, the SCAC study may also inform a potential broader development strategy across HPV-associated cancers.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Toripalimab
LOQTORZI (toripalimab-tpzi) is a next-generation PD-1 inhibitor and is the only available FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma. It is also being developed for additional tumor types with the goal of serving as a PD-1 inhibitor backbone for future treatment combinations that may extend survival for patients.

(Press release, Oncolytics Biotech, NOV 11, 2026, View Source [SID1234674624])

Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

On November 11, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, reported that the RADIANZ ("Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89") clinical trial is enrolling patients. RADIANZ is an imaging study of ⁸⁹Zr-Barecetamab-DFO using PET to guide the pan-tumor development of ²²⁵Ac-Barecetamab-DOTA (ATNM-400) in solid tumors outside of prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RADIANZ builds on ATNM-400’s first-in-human Phase 1 study in metastatic castration-resistant prostate cancer (mCRPC). ATNM-400 is an investigational, first-in-class Actinium-225 antibody radioconjugate targeting HER3, an antigen implicated in tumor survival and treatment resistance across multiple solid tumors. Initial results from that study were presented in October 2026 as an oral presentation at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM). The first three patients received ATNM-400 at 1.0 µCi/kg with no dose-limiting toxicities, HER3-targeted PET imaging showed tumor uptake retained through Day 7, and dose escalation advanced to 1.5 µCi/kg. The mCRPC study was also featured in at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026. At EANM 2026, Actinium presented preclinical data in NSCLC, colorectal and ovarian cancer models demonstrating the potential of ATNM-400 either as a single agent of in combination with approved drugs. The Company will also present additional breast cancer data for ATNM-400 at the San Antonio Breast Cancer Symposium (SABCS) taking place December 8-11, 2026.

"Dosing the first patient in RADIANZ is a major step in our pan-cancer strategy for ATNM-400," said Sandesh Seth, Actinium’s Chairman and CEO. "The initial clinical results we presented at EANM and the study we highlighted at ESMO (Free ESMO Whitepaper) established ATNM-400 in the clinic in prostate cancer. Our preclinical work across lung, breast, colorectal and ovarian cancer models demonstrates HER3 targeting potential beyond prostate cancer. With RADIANZ, we are now testing that potential in patients and building a clinical path for ATNM-400 across several large, treatment-resistant patient populations."

RADIANZ Study Design

The RADIANZ imaging study will include patients with various tumor types, including NSCLC, breast, colorectal, pancreatic and ovarian cancers who have progressed on standard-of-care therapy. Patients receive Zirconium-89-barecetamab PET imaging with time points up to two weeks to demonstrate tumor retention of the antibody radioconjugate (ARC) in different cancer types over this time span. The study evaluates biodistribution, tumor uptake, pharmacokinetics (PK), and dosimetry across different tumor types.

"Many patients with advanced solid tumors have few options once standard therapies stop working," said Steffen Heeger, MD, Actinium’s Chief Medical Officer. "HER3 has been implicated in resistance to targeted therapies, chemotherapy and hormonal therapies across several solid tumors. The RADIANZ Imaging study will give us further insights on how ATNM-400 can be further developed in different solid tumors beyond prostate cancer. We are excited at the potential ATNM-400 offers as the first of its kind HER3 targeting radiotherapy and the opportunity to develop a truly differentiated pan cancer product."

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis’ Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals’ TLX591-Tx, Clarity Pharmaceuticals’ ⁶⁷Cu-SAR-bisPSMA, Convergent Therapeutics’ CONV01-α, AstraZeneca’s AZD2265 (formerly FPI-2265), Curium’s lutetium-177 zadavotide guraxetan (¹⁷⁷Lu-PSMA-I&T), ARTBIO’s AB001 and AdvanCell’s ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink’s BNT326/YL202; Bristol Myers Squibb and SystImmune’s EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck’s patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

(Press release, Actinium Pharmaceuticals, NOV 11, 2026, View Source [SID1234674609])